Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00363727
Status:
COMPLETED
Last Update Posted:
2017-01-18
First Post:
2006-08-07
Brief Title:
Onset Motor Complications Using REQUIP CR Ropinirole Controlled-release As Add-on Therapy To L-dopa In Parkinsons
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Two Year Phase IIIb Randomised Multicenter Double-blind SINEMET Controlled Parallel Group Flexible Dose Study to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinsons Disease Subjects
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia abnormal twisting writhing movements in patients with Parkinsons Disease who have been taking levodopa for less than 2 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None